Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EPS (Basic) (2017 - 2025)

Dianthus Therapeutics has reported EPS (Basic) over the past 8 years, most recently at -$0.97 for Q3 2025.

  • Quarterly results put EPS (Basic) at -$0.97 for Q3 2025, down 31.08% from a year ago — trailing twelve months through Sep 2025 was -$3.5 (down 148.88% YoY), and the annual figure for FY2024 was -$2.55, up 69.82%.
  • EPS (Basic) for Q3 2025 was -$0.97 at Dianthus Therapeutics, down from -$0.89 in the prior quarter.
  • Over the last five years, EPS (Basic) for DNTH hit a ceiling of $8.95 in Q4 2023 and a floor of -$11.57 in Q4 2022.
  • Median EPS (Basic) over the past 4 years was -$0.74 (2024), compared with a mean of -$1.39.
  • Peak annual rise in EPS (Basic) hit 177.36% in 2023, while the deepest fall reached 1976.92% in 2023.
  • Dianthus Therapeutics' EPS (Basic) stood at -$11.57 in 2022, then soared by 177.36% to $8.95 in 2023, then crashed by 109.16% to -$0.82 in 2024, then decreased by 18.29% to -$0.97 in 2025.
  • The last three reported values for EPS (Basic) were -$0.97 (Q3 2025), -$0.89 (Q2 2025), and -$0.82 (Q1 2025) per Business Quant data.